Skip to main content
OpenTrials
Completed

NCT Number: NCT02753530

Study of Arimoclomol in Inclusion Body Myositis (IBM)

Funding Source - FDA Office of Orphan Products Development (OOPD). The purpose of this study is to evaluate the safety and efficacy of the study drug, arimoclomol in IBM patients.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Inclusion Body Myositis Muscular Diseases Musculoskeletal Diseases Myositis Myositis, Inclusion Body Nervous System Diseases Neuromuscular Diseases

Age range

45 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

University College of London, London, United Kingdom

Loading trial locations.

About this study

A Phase 2/3, randomized, double-blind, placebo-controlled, international, 20-month intervention study in patients with IBM.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Meet any of the European Neuromuscular Centre Inclusion Body Myositis research diagnostic criteria 2011 categories for IBM.
  • Demonstrate being able to arise from a chair without support from another person or device.
  • Able to ambulate at least 20 ft/6 meters with or without assistive device. Once arisen from the chair, participant may use any walking device, i.e. walker/frame, can, crutches, or braces. They cannot be supported by another person and cannot use furniture or wall for support.
  • Age at onset of weakness >45 years.
  • Body weight of >= 40 kg.
  • Able to give informed consent.

Exclusion criteria

  • History of any of the following excludes subject participation in the study: chronic infection particularly HIV or Hepatitis B or C; cancer other than basal cell cancer less than five years prior; or other chronic serious medical illnesses.
  • Presence of any of the following on routine blood screening: White blood cells (WBC) <3000; platelets < 100,000; hematocrit <30%; blood urea nitrogen (BUN) >30 mg/dL; creatinine >1.5 x upper limit of normal; symptomatic liver disease with serum albumin <3 g/dL.
  • History of most recent creatine kinase >15x the upper limit of normal without any other explanation besides IBM.
  • History of non-compliance with other therapies.
  • Use of testosterone except for physiologic replacement doses in case of androgen deficiency. Participants must have documented proof of the androgen deficiency.
  • Coexistence of other disease that would be likely to affect outcome measures
  • Drug or alcohol abuse within past three months.
  • Participation in a recent drug study in the last 30 days prior to the screening visit or use of a biologic agent less than 6 months prior to the screening visit.
  • Women who are lactating or unwilling to use adequate method of birth control who are not surgically sterile. Adequate birth control includes use of intrauterine device, abstinence, or oral contraceptives or a double barrier method, e.g condom plus diaphragm will be necessary for both male and female participants.
  • Participants taking >7.5 mg prednisolone or equivalent or participants on Intravenous Immunoglobulin Therapy (IVIg) or other immunosuppressants within the last 3 months.
  • Clinically significant renal or hepatic disease, as indicated by clinical laboratory assessment.

Treatment and study plan

Arimoclomol

Drug

2 capsules (2 x 124 mg arimoclomol base; equivalent to 2 x 200 mg arimoclomol citrate) taken 3 times daily during breakfast, early afternoon, and at bedtime

Placebo

Other

2 matched placebo capsules taken 3 times daily during breakfast, early afternoon, and at bedtime

Primary outcomes

  1. Change in Inclusion Body Myositis Functional Rating Scale (IBMFRS) Total Score

    Time frame: Change from Baseline to Month 20

    Measured by rate of decline in the IBMFRS between experimental and placebo groups. The IBMFRS is a 10-item questionnaire. Scores for each item range from 0 to 4. There is a total maximum score of 40 and minimum score of 0. The higher the score the better functional status of the person.

Secondary outcomes

  1. Change in Inclusion Body Myositis Functional Rating Scale (IBMFRS) Total Score

    Time frame: Change from Baseline to Month 12

    Measured by rate of decline in the IBMFRS between experimental and placebo groups. The IBMFRS is a 10-item questionnaire. Scores for each item range from 0 to 4. There is a total maximum score of 40 and minimum score of 0. The higher the score the better functional status of the person.

  2. Grip Strength

    Time frame: Change from Baseline to Month 12 and 20

    Unilateral hand grip strength in both hands measured using the Jamar Dynamometer. Results are for the stronger limb, as identified at baseline.

  3. Modified Timed up and go (mTUG)

    Time frame: Change from Baseline to Month 12 and Month 20

    The patient's combined ability to rise from a chair and walk 3 meters, turn around and walk back to the chair and sit down. The test was performed twice and the fastest time was used. The results were expressed as velocity in meters/second.

  4. Manual Muscle Testing (MMT), Total Score

    Time frame: Change from Baseline to Month 12 and Month 20

    The Manual Muscle Testing (MMT) scores the strength of 24 muscles (axial, proximal, and distal muscles, tested bilaterally) on a scale from 0 to 10 points. The total score is calculated as an average across the 24 muscles and ranges from 0 to 10. The total score will increase if a patient is getting stronger and decrease if a patient is getting weaker.

  5. 6 Minute Walk Test (6MWT); Distance After 6 Minutes (6MWD)

    Time frame: Change from Baseline to Month 12 and Month 20

    The distance patients could walk in 6 minutes. The distance walked in meters was recorded after 6 minutes.

  6. Short Form-36 (SF-36) Physical Component Score

    Time frame: Change from Baseline to Month 12 and Month 20

    Measured using the Short Form health survey with 36 items (SF-36). The questionnaire measures 8 health concepts which yields 2 summary measures: physical and mental health. The physical component score includes 4 scales of physical functioning (10 items), role limitations due to physical health (4 items), bodily pain (2 items), and general health (5 items). To score the SF-36, scales are standardized with a scoring algorithm to obtain a score ranging from 0 to 100, and the summary measure is calculated as the average score. Higher scores indicate better health status.

  7. Maximum Voluntary Isometric Contraction (MVICT) of Quadriceps

    Time frame: Change from Baseline to Month 12 and Month 20

    Unilateral strength of the knee extensor muscles on both limbs using the MicroFET hand-held dynamometer. Results are for the stronger limb, as identified at baseline.

  8. Health Assessment Questionnaire - Disability Index (HAQ-DI)

    Time frame: Change from Baseline to Month 12 and Month 20

    The disability index of the HAQ measures self-reported functional status (disability) including the patient's use of aids or devices and/or help from other persons. The scale is composed of 20 items in 8 domains (dressing and grooming, arising, eating, walking, hygiene, reach, grip, and common daily activities). Each domain has at least 2 subcategory items, scored on a scale from 0 to 3, and for each of the 8 domains the domain score was the highest score of the involved subcategory scores. The total score reported is an average over 8 domains and scores from at least 6 domains had to be available for the total score to be calculated. The average total score ranges from 0 to 3, and a higher score corresponds to a worsening in functional status.

  9. 2 Minute Walk Test (2MWT)

    Time frame: Change from Baseline to Month 12 and Month 20

    The distance patients could walk in 2 minutes (during the 6 Minute Walk Test) recorded in meters.

  10. Short Form-36 (SF-36) Mental Component Score

    Time frame: Change from Baseline to Month 12 and Month 20

    Measured using the Short Form health survey with 36 items (SF-36). The questionnaire measures 8 health concepts which yields 2 summary measures: physical and mental health. The mental component score is composed of energy/fatigue (4 items), social functioning (2 items), role limitations due to emotional problems (3 items), and emotional well-being (5 items). To score the SF-36, scales are standardized with a scoring algorithm to obtain a score ranging from 0 to 100, and the summary measure is calculated as the average score. Higher scores indicate better health status.

  11. Patient Global Impression of Severity (PGIS)

    Time frame: Change from Baseline to Month 12 and Month 20

    Patient-reported assessment of the impact of IBM on the ability to complete activities of daily living (e.g. dressing, walking, bathing) at the time of the assessment. The response options for the impact of IBM were "none" (i.e. no impact), "very mild", "mild", "moderate", "severe", and "very severe".

  12. Patient Global Impression of Change (PGIC)

    Time frame: Change from Baseline to Month 12 and Month 20

    Patient-reported assessment of the change from start of study treatment in the impact of IBM on the ability to complete activities of daily living (e.g. dressing, walking, bathing). The response options for change in impact were "very much worse", "much worse", "a little worse", "no change", "a little improved", "much improved", and "very much improved".

  13. Clinician Global Impression of Severity (CGIS)

    Time frame: Change from Baseline to Month 12 and Month 20

    Clinician-reported assessment of the severity of the patient's IBM symptoms at the time of the assessment. The response options were "none", "very mild", "mild", "moderate", "severe", and "very severe"

  14. Clinician Global Impression of Change (CGIC)

    Time frame: Change from Baseline to Month 12 and Month 20

    Clinician-reported assessment of the change from start of study treatment in the patient's IBM symptoms. The response options for change in IBM were "very much worse", "much worse", "a little worse", "no change", "a little improved", "much improved", and "very much improved".

  15. Falls and Near Falls

    Time frame: Accumulated number from Baseline to Month 20

    Falls and near falls registered by the participants in a diary

Sponsors and collaborators

Lead sponsor

ZevraDenmark

Industry

Collaborators

  • University College, London
  • University of Kansas Medical Center

Registry information

Official study title

Phase II Study of Arimoclomol for the Treatment of Sporadic Inclusion Body Myositis (IBM)

Important dates

Study start
2017
Primary completion
2021
Study completion
2021
First posted
Apr 28, 2016
Registry last updated
May 10, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.